Abstract:Porcine organs are rapidly rejected after transplantation into primate recipients due to the presence of preexisting immunoglobulins that bind to terminal galactose alpha1,3 galactose residues (alpha-galactosyl) present on porcine glycoproteins and glycolipids. Currently available immunosuppressive reagents have been largely ineffective at controlling the synthesis of these anti-Gal antibodies. Nonantigenic hapten polymers have been shown to be effective materials for blocking humoral immune responses in various model systems. We have developed a series of alpha-galactosyl glycoconjugate polymers and tested their ability to block anti-Gal antibody binding in vitro and in vivo. A galactose alpha1,3 galactose beta 1,4 GlcNAc trisaccharide free acid (TRFA) with a hexanoic acid spacer, containing five methylene groups and a carboxylic acid, was produced and coupled to a variety of polymeric backbones including dextran, branched poly(ethylene glycol) (PEG), and poly-L-lysine. The ability of monomeric TRFA and the alpha-galactosyl conjugates to block anti-Gal IgG and IgM binding was determined using a competition ELISA assay on defined HSA-Gal glycoconjugates and porcine microvascular endothelial cell substrates. We show that branched PEG carriers, with a TRFA sugar attached to each branch, exhibit enhanced antibody blocking ability compared to TRFA, but at higher target antigen densities these simple PEG conjugates are no more effective then an equivalent amount of TRFA in blocking anti-Gal IgM antibody interactions. In contrast, polymers of the branched PEG conjugates and linear conjugates made using dextran and poly-L-lysine were 2000 to 70000-fold more effective inhibitors of anti-Gal antibodies. In a study using nonhuman primates, a single dose infusion of polymeric PEG or dextran glycoconjugates dramatically reduced the level of circulating anti-Gal antibodies in cynomologus monkeys for at least 72 h. Glycoconjugates similar to these might be useful both to block anti-Gal interactions in vivo and to specifically control the induced anti-Gal immune response.

Minute lesions of esophageal cancer.

Effect of RNA Interference on Gal Alpha 1,3 Gal Expression in PIEC Cells

Expression of Human Alpha-Galactosidase Leads to Reduction of Major Xenoepitope Gal Alpha(1,3) Gal in Nih 3t3 Cell

Human Alpha Galactosidase and Alpha 1,2 Fucosyltransferase Concordantly Inhibit Xenoreactivity of NIH 3T3 Cells with Human Serum

Characterization of natural human anti-non-gal antibodies and their effect on activation of porcine gal-deficient endothelial cells

Floral patterning.

Alpha-Gal detectors in xenotransplantation research: a word of caution

[Xenogeneic Antigens and Immune Response in Pig to Man Xenograft].

Evaluation of different alpha-Galactosyl glycoconjugates for use in xenotransplantation

Effect of inoculation time on the bio-drying performance of combined hydrolytic-aerobic process.

Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation

Reduction in Xenogeneic Epitopes on Porcine Endothelial Cells by Periodate Oxidation

[Reactivity of Tissues of Chinese NJZ Pig to Human Serum].

Anti-pig Antibodies in Swine Veterinarian Serum: Implications for Clinical Xenotransplantation

Numerical Study of NO x Emissions from n-Heptane and 1-Heptene Counterflow Flames

Dermatitis Herpetiformis: An Immunologically Mediated Form of Gluten-Sensitive Enteropathy with Head and Neck Manifestations

Anti‐pig antibodies in swine veterinarian serum: Implications for clinical xenotransplantation

Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Gal alpha1,3Gal epitope

The Possible Role of Anti-Neu5Gc as an Obstacle in Xenotransplantation

Binding of human natural antibodies to nonalphaGal xenoantigens on porcine erythrocytes

Antisense Inhibition of Pig Α1,3galactosyl‐transferase Leads to a Reduction in Expression of the Major Target for Human Natural Antibodies on Pig Vascular Endothelial Cells